| __timestamp | Cytokinetics, Incorporated | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 17268000 | 44820000 |
| Thursday, January 1, 2015 | 19667000 | 82080000 |
| Friday, January 1, 2016 | 27823000 | 97130000 |
| Sunday, January 1, 2017 | 36468000 | 121271000 |
| Monday, January 1, 2018 | 31282000 | 153548000 |
| Tuesday, January 1, 2019 | 39610000 | 202541000 |
| Wednesday, January 1, 2020 | 52820000 | 245164000 |
| Friday, January 1, 2021 | 96803000 | 285773000 |
| Saturday, January 1, 2022 | 177977000 | 325998000 |
| Sunday, January 1, 2023 | 173612000 | 332540000 |
Unveiling the hidden dimensions of data
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, from 2014 to 2023, Cytokinetics, Incorporated and PTC Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. Cytokinetics started with a modest $17 million in 2014, growing over tenfold to approximately $174 million by 2023. This represents a staggering increase of over 900%, highlighting their aggressive expansion and investment in administrative capabilities.
Conversely, PTC Therapeutics began with $45 million in 2014, reaching $333 million in 2023, marking a 640% increase. This growth underscores their strategic focus on scaling operations. Notably, PTC consistently outspent Cytokinetics, reflecting their larger operational scale. These trends offer a window into each company's strategic priorities and market positioning, providing valuable insights for investors and industry analysts alike.
AbbVie Inc. and Cytokinetics, Incorporated: SG&A Spending Patterns Compared
Alnylam Pharmaceuticals, Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Catalent, Inc. vs Cytokinetics, Incorporated
SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and PTC Therapeutics, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Cytokinetics, Incorporated or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Ionis Pharmaceuticals, Inc. vs PTC Therapeutics, Inc.
PTC Therapeutics, Inc. or Veracyte, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for PTC Therapeutics, Inc. and Agios Pharmaceuticals, Inc.